Vnitr Lek 2023, 69(5):322-328 | DOI: 10.36290/vnl.2023.063

Pharmacological profile of mepolizumab

Norbert Pauk
Klinika pneumologie 3. LF UK a Fakultní nemocnice Bulovka, Praha

An elevated number of eosinophils have been implicated in several type 2 inflammatory chronic diseases that occur at various sites in the body. Over the past 20 years, our knowledge of diseases associated with increased numbers of eosinophils has advanced thanks to the development of drugs that can reduce or even eliminate eosinophils. One such agent is mepolizumab, a humanized monoclonal antibody that binds to interleukin -5 (IL-5). This article briefly and clearly summarizes the pharmacological profile of mepolizumab and its current indications for a number of chronic eosinophilic diseases.

Keywords: mepolizumab, severe eosinophilic asthma (SEA), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES).

Accepted: August 24, 2023; Published: September 12, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pauk N. Pharmacological profile of mepolizumab. Vnitr Lek. 2023;69(5):322-328. doi: 10.36290/vnl.2023.063.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Matera MG, Calzetta L, Rogliani P, Cazzola M. Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. Respir Med. 2019 Jul;153:3-13. doi: 10.1016/j.rmed.2019.05.005. Epub 2019 May 13. PMID: 31136930. Go to original source... Go to PubMed...
    2. Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021 Mar 18;184(6):1469-1485. doi: 10.1016/j.cell.2021.02.016. Epub 2021 Mar 11. Erratum in: Cell. 2021 Apr 29;184(9):2521-2522. PMID: 33711259. Go to original source... Go to PubMed...
    3. GINA (Global Initiative for Asthma). Global Strategy for Asthma Management and Prevention. 2022. http://www.ginasthma.org
    4. Teřl M, Sedlák V, Krčmová I. Doporučený postup diagnostiky a léčby těžkého astmatu. Stud. Pneumol. Phthiseol. 82, č. 4, 2022.
    5. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 Aug 18;380(9842):651-9. doi: 10.1016/S0140-6736(12)60988-X. PMID: 22901886. Go to original source... Go to PubMed...
    6. Ortega HG, Liu MC, Pavord ID, et al; Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8. Erratum in: N Engl J Med. 2015 Apr 30;372(18):1777. PMID: 25199059. Go to original source... Go to PubMed...
    7. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8. PMID: 25199060. Go to original source... Go to PubMed...
    8. Gibson PG, Prazma CM, Chupp GL, et al. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. Respir Res. 2021 Jun 7;22(1):171. doi: 10.1186/s12931-021-01746-4. PMID: 34098955; PMCID: PMC8182929. Go to original source... Go to PubMed...
    9. Khurana S, Brusselle GG, Bel EH, et al. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clin Ther. 2019 Oct;41(10):2041-2056.e5. doi: 10.1016/j.clinthera.2019.07.007. Epub 2019 Aug 22. PMID: 31447130. Go to original source... Go to PubMed...
    10. Harrison T, Canonica GW, Chupp G, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020 Oct 15;56(4):2000151. doi: 10.1183/13993003.00151-2020. PMID: 32817259; PMCID: PMC7559868. Go to original source... Go to PubMed...
    11. Pilette C, Canonica GW, Chaudhuri R, et al. REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2646-2656. doi: 10.1016/j.jaip.2022.05.042. Epub 2022 Jun 24. PMID: 35753668. Go to original source... Go to PubMed...
    12. Hellings PW, Verhoeven E, Fokkens WJ. State-of-the-art overview on biological treatment for CRSwNP. Rhinology. 2021 Apr 1;59(2):151-163. doi: 10.4193/Rhin20.570. PMID: 33459728. Go to original source... Go to PubMed...
    13. Han JK, Bachert C, Fokkens W, Desrosiers M, et al. SYNAPSE study investigators. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Oct;9(10):1141-1153. doi: 10.1016/S2213-2600(21)00097-7. Epub 2021 Apr 16. PMID: 33872587. Go to original source... Go to PubMed...
    14. Raffray L, Guillevin L. Updates for the treatment of EGPA. Presse Med. 2020 Oct;49(3):104036. doi: 10.1016/j.lpm.2020.104036. Epub 2020 Jul 8. PMID: 32652104. Go to original source... Go to PubMed...
    15. Moiseev S, Cohen Tervaert JW, Arimura Y, et al. 2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev. 2020 Sep;19(9):102618. doi: 10.1016/j.autrev.2020.102618. Epub 2020 Jul 12. PMID: 32663621. Go to original source... Go to PubMed...
    16. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017 May 18;376(20):1921-1932. doi: 10.1056/NEJMoa1702079. PMID: 28514601; PMCID: PMC5548295. Go to original source... Go to PubMed...
    17. Žurkova M, Jakubec P, Lošťáková V, et al.Mepolizumab v léčbě eozinofilní granulomatózy s polyangiitidou. Remedia. 2023;33:1-6.
    18. Requena G, van den Bosch J, Akuthota P, et al. Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2125-2134. doi: 10.1016/j.jaip.2022.03.034. Epub 2022 Apr 22. PMID: 35470096. Go to original source... Go to PubMed...
    19. Roufosse F, Kahn JE, Rothenberg ME, et al. HES Mepolizumab study group. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020 Dec;146(6):1397-1405. doi: 10.1016/j.jaci.2020.08.037. Epub 2020 Sep 18. PMID: 32956756; PMCID: PMC9579892. Go to original source... Go to PubMed...
    20. Domingo Ribas C, Carrillo Díaz T, Blanco Aparicio M, et al. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study. Drugs. 2021 Oct;81(15):1763-1774. doi: 10.1007/s40265-021-01597-9. Epub 2021 Sep 29. Erratum in: Drugs. 2021 Oct 21;: PMID: 34586602; PMCID: PMC8550660. Go to original source... Go to PubMed...
    21. Nucala 100 mg inj plv sol 1, Available from: www.sukl.cz.
    22. Národní centra těžkého astmatu; Available from: www.tezke-astma.cz.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.